TNF-α gene silencing using polymerized siRNA/Thiolated glycol chitosan nanoparticles for rheumatoid arthritis

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 397-408

  Lee, So Jin ^a   Lee, Aeju ^a,b   Hwang, Seung Rim ^c   Park, Jong Sung ^d   Jang, Jiyeon ^d   Huh, Myung Sook ^e   Jo, Dong Gyu ^d   Yoon, Soo Young ^b   Byun, Youngro ^f   Kim, Sun Hwa ^a   Kwon, Ick Chan ^a,g   Youn, Inchan ^a   Kim, Kwangmeyung ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Chosun University   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Korea Intellectual Property Office   (South Korea)

^f Seoul National University   (South Korea)

^g Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; GLYCOL CHITOSAN; METHOTREXATE; NANOPARTICLE; SMALL INTERFERING RNA; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOL-CHITOSAN; THIOL DERIVATIVE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; BONE MASS; CELL TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DYNAMIC LIGHT SCATTERING; ENCAPSULATION; GEL RETARDATION ANALYSIS; GENE SILENCING; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MACROPHAGE CULTURE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NANOPROBE; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; PROTEIN EXPRESSION; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; ARTHRITIS, RHEUMATOID; BLOOD; CELL LINE; CHEMISTRY; DISEASE MODEL; EXPERIMENTAL ARTHRITIS; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; CHITOSAN; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE SILENCING; MACROPHAGES; MALE; MICE; NANOPARTICLES; RNA, SMALL INTERFERING; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895903061     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.245     Document Type: Article

References (37)

1. McInnes, IB and Schett, G (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442.
2. Arend, WP (2001). Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 45: 101-106.
3. Feldmann, M and Maini, RN (2003). Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9: 1245-1250.
4. Catrina, AI, Lampa, J, Ernestam, S, af Klint, E, Bratt, J, Klareskog, L et al. (2002). Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41: 484-489.
5. Zeisel, MB, Druet, VA, Wachsmann, D and Sibilia, J (2005). MMP-3 expression and release by rheumatoid arthritis fibroblast-like synoviocytes induced with a bacterial ligand of integrin alpha5beta1. Arthritis Res Ther 7: R118-R126.
6. Elliott, MJ, Maini, RN, Feldmann, M, Kalden, JR, Antoni, C, Smolen, JS et al. (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
7. Airò, P, Antonioli, CM, Vianelli, M and Toniati, P (2002). Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41: 347-349.
8. Gardam, MA, Keystone, EC, Menzies, R, Manners, S, Skamene, E, Long, R et al. (2003). Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148-155.
9. Kole, R, Krainer, AR and Altman, S (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11: 125-140.
10. Martinez, J, Patkaniowska, A, Urlaub, H, Lührmann, R and Tuschl, T (2002). Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110: 563-574.
11. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
12. Oh, YK and Park, TG (2009). siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61: 850-862.
13. Bumcrot, D, Manoharan, M, Koteliansky, V and Sah, DW (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719.
14. Han, SE, Kang, H, Shim, GY, Suh, MS, Kim, SJ, Kim, JS et al. (2008). Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm 353: 260-269.
15. Akinc, A, Zumbuehl, A, Goldberg, M, Leshchiner, ES, Busini, V, Hossain, N et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569.
16. Hong, CA, Kim, JS, Lee, SH, Kong, WH, Park, TG, Mok, H et al. (2013). Reductively dissociable siRNA-polymer hybrid nanogels for efficient targeted gene silencing. Adv Funct Mater 23: 316-322.
17. Ye, C, Bhan, AK, Deshpande, V, Shankar, P and Manjunath, N (2013). Silencing TNF-a in macrophages and dendritic cells for arthritis treatment. Scand J Rheumatol 42: 266-269.
18. Crielaard, BJ, Lammers, T, Schiffelers, RM and Storm, G (2012). Drug targeting systems for inflammatory disease: one for all, all for one. J Control Release 161: 225-234.
19. Jere, D, Kim, JE, Arote, R, Jiang, HL, Kim, YK, Choi, YJ et al. (2009). Akt1 silencing efficiencies in lung cancer cells by sh/si/ssiRNA transfection using a reductable polyspermine carrier. Biomaterials 30: 1635-1647.
20. Wiradharma, N, Khan, M, Tong, YW, Wang, S, and Yang, YY (2008). Self-assembled cationic peptide nanoparticles capable of inducing efficient gene expression in vitro. Adv Funct Mater 18: 943-951.
21. Bolcato-Bellemin, AL, Bonnet, ME, Creusat, G, Erbacher, P and Behr, JP (2007). Sticky overhangs enhance siRNA-mediated gene silencing. Proc Natl Acad Sci USA 104: 16050-16055.
22. Mok, H, Lee, SH, Park, JW and Park, TG (2010). Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater 9: 272-278.
23. Lee, SJ, Huh, MS, Lee, SY, Min, S, Lee, S, Koo, H et al. (2012). Tumor-homing polysiRNA/ glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew Chem Int Ed Engl 51: 7203-7207.
24. Lee, SY, Huh, MS, Lee, S, Lee, SJ, Chung, H, Park, JH et al. (2010). Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J Control Release 141: 339-346.
25. Mulherin, D, Fitzgerald, O and Bresnihan, B (1996). Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39: 115-124.
26. Onishi, H and Machida, Y (1999). Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials 20: 175-182.
27. Ryu, JH, Lee, A, Chu, JU, Koo, H, Ko, CY, Kim, HS et al. (2011). Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arthritis Rheum 63: 3824-3832.
28. Paleolog, EM (2002). Angiogenesis in rheumatoid arthritis. Arthritis Res 4 (suppl 3): S81-S90.
29. Baluk, P, Hirata, A, Thurston, G, Fujiwara, T, Neal, CR, Michel, CC et al. (1997). Endothelial gaps: time course of formation and closure in inflamed venules of rats. Am J Physiol 272: L155-L170.
30. Yuan, F, Quan, LD, Cui, L, Goldring, SR and Wang, D (2012). Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev 64: 1205-1219.
31. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
32. Kobayashi, K, Takahashi, N, Jimi, E, Udagawa, N, Takami, M, Kotake, S et al. (2000). Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275-286.
33. Howard, KA, Paludan, SR, Behlke, MA, Besenbacher, F, Deleuran, B and Kjems, J (2009). Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 17: 162-168.
34. Saito, G, Swanson, JA and Lee, KD (2003). Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 55: 199-215.
35. Hassan, MQ, Hadi, RA, Al-Rawi, ZS, Padron, VA and Stohs, SJ (2001). The glutathione defense system in the pathogenesis of rheumatoid arthritis. J Appl Toxicol 21: 69-73.
36. Huh, MS, Lee, SY, Park, S, Lee, S, Chung, H, Lee, S et al. (2010). Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumorbearing mice. J Control Release 144: 134-143.
37. Brand, DD, Latham, KA and Rosloniec, EF (2007). Collagen-induced arthritis. Nat Protoc 2: 1269-1275.